Dr. Liu received her Ph.D. from Chinese Academy of Sciences in 2014 and is currently continuing her post-doctoral research at Brigham and Women’s Hospital (BWH), Harvard Medical School (HMS). She has extensive experience in the research fields of nanomedicine and biomaterials, and has developed many multifunctional nanomaterials for cancer imaging and therapy. Dr. Liu is currently developing innovative theranostic biomaterials and nanotechnologies for safe and effective delivery of biomacromolecules (e.g. siRNA) and small molecular drugs for imaging-guided therapy of diseases such as cancer and stroke.
Dr. Mohammad Ariful Islam obtained his Bachelor in Biotechnology and Genetic Engineering from the University of Development Alternative, Bangladesh in 2007. He earned his Master (Feb 2010) and Doctoral degree (Feb 2013) from Seoul National University, South Korea. He developed a number of smart polymeric carriers to deliver genes (DNA, siRNA, microRNA) for cancer therapy and subunit antigens for vaccine therapy. Dr. Islam achieved several research awards including “Brain Korea 21 2012); the “Best Young Scientist” (2013); the ‘Research Excellence Award’ (2013) from Seoul National University. He has authored about 30 peer-reviewed articles as well as Book Chapters (as far as 2016) and few of his research works have been issued/pending national and international patents. Currently, he is a Postdoctoral Fellow in the Farokhzad Lab at Harvard Medical School and Brigham & Women’s Hospital (HMS/BWH) since March 2014, where he has been working on developing mRNA nanotherapeutics for cancer immunotherapy, gene therapy as well as asthma nanotherapeutics.
Dr. Phei Er Saw is a post-doctoral fellow in the Farokhzad Lab at Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH). She received her Ph.D. in the Department of Biological Sciences in Korea Advanced Institute of Science and Technology (KAIST) for her research work on bio-nanomedicine in South Korea (2014). She then served as postdoctoral fellow in the Department of Biological Sicences, KAIST (March 2014 –May 2015) and is currently continuing her post-doctoral research in the Laboratory of Nanomedicine and Biomaterials at HMS (2015-2016). She currently leads several projects aimed at the development of multi-stage targeted nanoparticles encapsulating small-biologic drug conjugates, lipid-based novel nanomaterials for various applications and natural-product based nanoparticle for cancer therapy.
Dr. Wei Tao is a Postdoctoral Research Fellow in the Farokhzad Lab at Harvard Medical School and Brigham and Women’s Hospital. He received his Bachelor degree in Biomedical Engineering (2011) from Huazhong University of Science and Technology and Doctoral degree in Biology (2015) from Tsinghua University. During his Ph.D. study, he also attended Harvard University as a visiting PhD student (2014). He has authored over 40 peer-reviewed papers in high impact journals, such as Adv Mater, Angew Chem, Chem Soc Rev, Nano Lett, PNAS and so on. Dr. Tao has also received many awards such as Tsinghua-“Ling Feng” Instructor Award (2015), Student Fellowship from World Pharma Congress (2014), National Scholarship from Ministry of Education of the People’s Republic of China (2012, 2014), Hong Kong Qiu Shi Science and Technologies Foundation Award (2010) and so on. His current research interest is developing novel theranostic 2D nanomaterials and multi-stage polymeric nanomedicines for biomedical applications, as well as revealing their nano-bio interactions.
Dr. Claudia Corbo received her PhD degree in Molecular Oncology at the European School of Molecular Medicine (www.semm.it), joint between the University of Naples “Federico II” and University of Milan, in 2012. She did her first post-doctoral training in the research organization CEINGE, Advanced Biotechnologies (Naples, Italy) where her research was mainly devoted on the discovery of tumor biomarkers by means of proteomic and mass spectrometry. In 2013, she joined the Center for Biomimetic Medicine at the Houston Methodist Research Institute (Houston, TX) to perform her second post-doc. Her research was focused on understanding events at the nano–bio interface, with particular focusing on bio-inspired nanoparticles. She currently holds a postdoctoral fellowship at Brigham and Women’s Hospital, Harvard Medical School. She is working on protein corona formation and nanoparticle/cell interaction to explore possible novel nano-therapeutic cancer applications.
Dr. Shahed Behzadi received his Ph.D. from Max Planck Institute for Polymer Research (MPI-P) in 2016 and he currently holds a postdoctoral fellowship position at Brigham and Women’s Hospital (BWH), Harvard Medical School (HMS). The main subject of his doctoral project was to develop advanced stimuli-responsive organic and inorganic nanocapsules with enhanced capabilities for selective-release of payloads. Dr. Behzadi is currently developing cutting-edge nanotechnology drug delivery systems with the ability to diagnose cancerous cells, target infecting bacteria and induce bone regeneration. The ultimate goal of his current research is to clinically translate these nanomedicines.
Dr. Jianxun Ding is currently a Postdoctoral Research Fellow in the Farokhzad lab, Brigham and Women’s Hospital (BWH), Harvard Medical School (HMS). He received his B.S. degree from the University of Science and Technology of China (USTC) in 2007, and obtained his Ph.D. degree from Changchun Institute of Applied Chemistry (CIAC), Chinese Academy of Sciences (CAS), in 2013. During his Ph.D., he was awarded the 2012 President Excellence Award of CAS and more than 10 other awards. He has published a series of high-impact academic papers and applied for over 60 Chinese invention patents in the field of biomedical polymer materials. His research interests focus on (1) synthesis of functional biodegradable polymers, (2) exploitation of stimuli-responsive polymers for controlled drug delivery, and (3) preparation of polymer nanoparticles as adjuvants of immunotherapy.